GlassScriptPhysician profile
Andrew M Goldenberg
NPI 1932272697
$8,092.56
in general payments reported to CMS, 2019-2025
34 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $457 · 2021: $1,076 · 2022: $1,276 · 2023: $1,865 · 2024: $1,815 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,859 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,858.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,048.00 | 2019-2025 | |
| Janssen Biotech, INC. | $988.32 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $778.13 | 2020-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $556.11 | 2019-2025 | |
| Madrigal Pharmaceuticals | $496.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $411.21 | 2022-2024 | Gi Genius, Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $389.42 | 2019-2024 | Entyvio, Gattex |
| Ardelyx, INC. | $292.61 | 2023-2025 | Ibsrela |
| Celgene Corporation | $281.13 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $204.84 | 2021-2024 | Watchman Flx |
| Pfizer INC. | $202.35 | 2019-2025 | |
| Genzyme Corporation | $189.74 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $162.08 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $115.48 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $112.20 | 2019-2025 | Linzess |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $108.92 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $84.72 | 2020-2022 | |
| Fresenius Kabi USA, LLC | $83.84 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $78.94 | 2019-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $75.12 | 2025 | |
| Lilly USA, LLC | $71.12 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $58.66 | 2024-2025 | Voquezna |
| Organon LLC | $51.63 | 2022-2023 | Hadlima, Renflexis |
| Allergan, INC. | $45.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.58 | 2023-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $24.66 | 2023 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $24.41 | 2021 | |
| Qol Medical, LLC | $23.92 | 2019 | |
| W. L. Gore & Associates, INC. | $18.08 | 2021 | |
| Concordia Pharmaceuticals INC. | $16.76 | 2019 | |
| Lucid Diagnostics INC. | $16.72 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.77 | 2022 | |
| Evoke Pharma, INC. | $14.47 | 2021 | |
| Meridian Bioscience INC. | $8.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.